Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
Esophageal cancer is the sixth most common cancer worldwide. Approximately 50% of patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have demonstrated that neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for patients with resectable disease. However...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1264912/full |
| _version_ | 1797666491332558848 |
|---|---|
| author | Yan Lin Huan-Wei Liang Yang Liu Xin-Bin Pan |
| author_facet | Yan Lin Huan-Wei Liang Yang Liu Xin-Bin Pan |
| author_sort | Yan Lin |
| collection | DOAJ |
| description | Esophageal cancer is the sixth most common cancer worldwide. Approximately 50% of patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have demonstrated that neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for patients with resectable disease. However, a pathological complete response is frequently not achieved, and most patients have a poor prognosis. The CheckMate 577 trial demonstrates that nivolumab adjuvant therapy improves disease-free survival in patents without a pathological complete response. However, there are still numerous clinical questions of concern that remain controversial based on the results of the subgroup analysis. In this review, we aim to offer constructive suggestions addressing the clinical concerns raised in the CheckMate 577 trial. |
| first_indexed | 2024-03-11T19:59:08Z |
| format | Article |
| id | doaj.art-18c84529d5394d7699ede722511f46a5 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T19:59:08Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-18c84529d5394d7699ede722511f46a52023-10-04T09:55:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-10-011410.3389/fimmu.2023.12649121264912Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trialYan Lin0Huan-Wei Liang1Yang Liu2Xin-Bin Pan3Department of Gastroenterology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, ChinaDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, ChinaDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, ChinaDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, ChinaEsophageal cancer is the sixth most common cancer worldwide. Approximately 50% of patients have locally advanced disease. The CROSS and NEOCRTEC5010 trials have demonstrated that neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for patients with resectable disease. However, a pathological complete response is frequently not achieved, and most patients have a poor prognosis. The CheckMate 577 trial demonstrates that nivolumab adjuvant therapy improves disease-free survival in patents without a pathological complete response. However, there are still numerous clinical questions of concern that remain controversial based on the results of the subgroup analysis. In this review, we aim to offer constructive suggestions addressing the clinical concerns raised in the CheckMate 577 trial.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1264912/fullesophageal canceradjuvant immunotherapynivolumabCheckMate 577subgroup |
| spellingShingle | Yan Lin Huan-Wei Liang Yang Liu Xin-Bin Pan Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial Frontiers in Immunology esophageal cancer adjuvant immunotherapy nivolumab CheckMate 577 subgroup |
| title | Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial |
| title_full | Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial |
| title_fullStr | Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial |
| title_full_unstemmed | Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial |
| title_short | Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial |
| title_sort | nivolumab adjuvant therapy for esophageal cancer a review based on subgroup analysis of checkmate 577 trial |
| topic | esophageal cancer adjuvant immunotherapy nivolumab CheckMate 577 subgroup |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1264912/full |
| work_keys_str_mv | AT yanlin nivolumabadjuvanttherapyforesophagealcancerareviewbasedonsubgroupanalysisofcheckmate577trial AT huanweiliang nivolumabadjuvanttherapyforesophagealcancerareviewbasedonsubgroupanalysisofcheckmate577trial AT yangliu nivolumabadjuvanttherapyforesophagealcancerareviewbasedonsubgroupanalysisofcheckmate577trial AT xinbinpan nivolumabadjuvanttherapyforesophagealcancerareviewbasedonsubgroupanalysisofcheckmate577trial |